Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News and Analysis

Turning off the "master switch" for cancer

Heather Kent
CMAJ May 16, 2000 162 (10) 1475;
Heather Kent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Researchers at the British Columbia Cancer Agency (BCCA) have made a major breakthrough with the discovery of a "master switch" that can turn off tumour growth in several common types of cancer. The findings could result in promising new treatments for cancer (Proc Natl Acad Sci USA 2000;97[7]:3207-12).

Dr. Shoukat Dedhar, a senior scientist at the agency, and his colleagues at Vancouver's Kinetek Pharmaceuticals have found a connection between a key tumour suppressor gene called PTEN and the integrin-linked kinase (ILK) protein, which plays a major role in the growth of cancer cells.

ILK prevents tumour cell death, allowing tumours to grow (the "on" switch). In normal cells, the PTEN gene controls ILK (providing the "off" switch). However, PTEN is mutated or absent in 60% of all solid types of cancer. Dedhar's research indicates that ILK is hyperactive in many of these types of cancer, including prostate, breast, brain, lung and colon cancer. Using human lung, prostate and colon cancer cells, Dedhar and Kinetek's Dr. Jasbinder Sanghera have developed promising ILK-inhibiting compounds that block the formation of new blood vessels and prevent the spread of tumour cells. Experimenting with mice in which human tumours had been transplanted, as well as in human prostate cancer cells, the researchers found that ILK inhibitors induced cell death in prostate cancer cells and reduced the spread of the tumours. FIGURE

Figure

Figure. Diagram shows how ILK functions as the "on" switch within cells, inducing cell responses seen in cancer, whereas the PTEN gene functions as the "off" switch, preventing this process.

"This is both amazing and exhilarating," said Dedhar. "Inhibiting ILK may not only result in inhibiting growth of the primary tumour but may also lead to reducing the subsequent spread of the tumour cells. And unlike standard chemotherapy agents, these inhibitors do not appear to kill or harm healthy cells. We now know that if we inhibit ILK, we might be able to treat tumours in novel ways. We envisage that these anti-ILK compounds may be used with low-dose conventional chemotherapy."

Dr. Victor Ling, vice-president of research at the BCCA, commented: "This is exciting news for cancer patients everywhere. A targeted therapy with fewer side effects will mean better results for those living with cancer."

Phase 1 clinical trials of ILK inhibitors are expected to start within 2 years.

PreviousNext
Back to top

In this issue

CMAJ
Vol. 162, Issue 10
16 May 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Turning off the "master switch" for cancer
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Turning off the "master switch" for cancer
Heather Kent
CMAJ May 2000, 162 (10) 1475;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Turning off the "master switch" for cancer
Heather Kent
CMAJ May 2000, 162 (10) 1475;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Will Canada follow US lead on RU 486?
  • Gene mutation may explain multiple-birth pregnancies
  • Greening of health care goal of new coalition
Show more News and Analysis

Similar Articles

Collections

  • Topics
    • Cancer & oncology
    • Genetics

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire